CN101861333A - 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物 - Google Patents

包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物 Download PDF

Info

Publication number
CN101861333A
CN101861333A CN200880116227A CN200880116227A CN101861333A CN 101861333 A CN101861333 A CN 101861333A CN 200880116227 A CN200880116227 A CN 200880116227A CN 200880116227 A CN200880116227 A CN 200880116227A CN 101861333 A CN101861333 A CN 101861333A
Authority
CN
China
Prior art keywords
insulin
glp
pharmaceutical composition
glu
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN200880116227A
Other languages
English (en)
Chinese (zh)
Inventor
A·普卢姆
D·B·斯蒂恩斯加尔德
J·K·汤姆森
M·施莱因
A·S·K·马库森
C·波尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN201611159339.1A priority Critical patent/CN107115523A/zh
Priority to CN201710279962.9A priority patent/CN107412742B/zh
Publication of CN101861333A publication Critical patent/CN101861333A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN200880116227A 2007-11-16 2008-11-14 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物 Withdrawn CN101861333A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201611159339.1A CN107115523A (zh) 2007-11-16 2008-11-14 包含glp‑1肽或毒蜥外泌肽‑4和基础胰岛素肽的药物组合物
CN201710279962.9A CN107412742B (zh) 2007-11-16 2008-11-14 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07120880.5 2007-11-16
EP07120880 2007-11-16
PCT/EP2008/065601 WO2009063072A2 (en) 2007-11-16 2008-11-14 Pharmaceutical compositions containing insulin and an insulinotropic peptide

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710279962.9A Division CN107412742B (zh) 2007-11-16 2008-11-14 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
CN201611159339.1A Division CN107115523A (zh) 2007-11-16 2008-11-14 包含glp‑1肽或毒蜥外泌肽‑4和基础胰岛素肽的药物组合物

Publications (1)

Publication Number Publication Date
CN101861333A true CN101861333A (zh) 2010-10-13

Family

ID=40639234

Family Applications (3)

Application Number Title Priority Date Filing Date
CN200880116227A Withdrawn CN101861333A (zh) 2007-11-16 2008-11-14 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
CN201611159339.1A Pending CN107115523A (zh) 2007-11-16 2008-11-14 包含glp‑1肽或毒蜥外泌肽‑4和基础胰岛素肽的药物组合物
CN201710279962.9A Active CN107412742B (zh) 2007-11-16 2008-11-14 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201611159339.1A Pending CN107115523A (zh) 2007-11-16 2008-11-14 包含glp‑1肽或毒蜥外泌肽‑4和基础胰岛素肽的药物组合物
CN201710279962.9A Active CN107412742B (zh) 2007-11-16 2008-11-14 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物

Country Status (15)

Country Link
US (1) US8937042B2 (enExample)
EP (2) EP2597103B1 (enExample)
JP (2) JP5241849B2 (enExample)
CN (3) CN101861333A (enExample)
BR (1) BRPI0820535B8 (enExample)
CA (1) CA2705821A1 (enExample)
DK (1) DK2597103T3 (enExample)
ES (2) ES2430042T3 (enExample)
HU (2) HUE030383T2 (enExample)
MX (1) MX2010005245A (enExample)
NO (1) NO2017015I1 (enExample)
PL (2) PL2209800T3 (enExample)
PT (1) PT2597103T (enExample)
WO (1) WO2009063072A2 (enExample)
ZA (1) ZA201003019B (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103813801A (zh) * 2011-09-01 2014-05-21 赛诺菲-安万特德国有限公司 在治疗神经变性性疾病中使用的药物组合物
CN106559984A (zh) * 2014-05-29 2017-04-05 韩美药品株式会社 用于治疗糖尿病的包含长效胰岛素类似物缀合物和长效促胰岛素肽缀合物的组合物
CN109999180A (zh) * 2011-06-02 2019-07-12 韩美科学株式会社 用于治疗糖尿病的包括长效胰岛素缀合物和长效促胰岛素肽缀合物的组合物
CN110087674A (zh) * 2016-12-16 2019-08-02 诺和诺德股份有限公司 含胰岛素的药物组合物
US10647753B2 (en) 2015-08-28 2020-05-12 Hanmi Pharm. Co., Ltd. Insulin analogs and use thereof
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
WO2021142736A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Dosing regimen of glp-1
US11396534B2 (en) 2016-09-23 2022-07-26 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0413276B8 (pt) * 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
DK2254906T3 (en) 2008-03-18 2017-01-23 Novo Nordisk As Protease-stabilized acylated insulin analogues
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
WO2010049488A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
PE20120017A1 (es) 2009-02-13 2012-02-12 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv, opcionalmente, un agente antidiabetico adicional, y sus usos
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2014203421B2 (en) * 2010-05-19 2016-07-07 Sanofi Long-acting formulations of insulins
AU2012216648C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
KR20230051307A (ko) * 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
FR2984749A1 (fr) * 2011-12-23 2013-06-28 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
CN103889442B (zh) * 2011-08-10 2016-12-28 阿道恰公司 至少一种基础胰岛素的可注射溶液
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
CN113730555A (zh) 2012-01-09 2021-12-03 阿道恰公司 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
FR2985429B1 (fr) * 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
FR3001895B1 (fr) * 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
ES2709339T3 (es) 2013-04-03 2019-04-16 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX369656B (es) 2014-01-20 2019-11-15 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma.
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2018055539A1 (en) * 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
KR20240167712A (ko) * 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
CN110669680A (zh) * 2019-11-04 2020-01-10 张少清 黑酵母菌的培养方法及从黑酵母菌中提取β葡聚糖的工艺
WO2021105393A1 (en) 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
CA3190959A1 (en) * 2020-08-12 2022-02-17 Txp Pharma Ag Exendin-4 peptide analogues
WO2022268208A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含酰化胰岛素的药物组合物
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE69428134T2 (de) 1993-09-17 2002-05-02 Novo Nordisk A/S, Bagsvaerd Acyliertes insulin
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20010041786A1 (en) 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
ATE307603T1 (de) 1998-12-22 2005-11-15 Lilly Co Eli Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2002000222A1 (en) 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for the treatment of cancer
CN1635900A (zh) 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
US7179788B2 (en) 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
EP1684793B1 (en) 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
WO2005067898A2 (en) * 2004-01-07 2005-07-28 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
WO2006014673A2 (en) * 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
US20080280814A1 (en) * 2004-09-17 2008-11-13 Novo Nordisk A/S Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
JP5248113B2 (ja) * 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
EP2386572B1 (en) 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109999180A (zh) * 2011-06-02 2019-07-12 韩美科学株式会社 用于治疗糖尿病的包括长效胰岛素缀合物和长效促胰岛素肽缀合物的组合物
CN103813801A (zh) * 2011-09-01 2014-05-21 赛诺菲-安万特德国有限公司 在治疗神经变性性疾病中使用的药物组合物
CN108969756A (zh) * 2011-09-01 2018-12-11 赛诺菲-安万特德国有限公司 在治疗神经变性性疾病中使用的药物组合物
CN106559984A (zh) * 2014-05-29 2017-04-05 韩美药品株式会社 用于治疗糖尿病的包含长效胰岛素类似物缀合物和长效促胰岛素肽缀合物的组合物
US10647753B2 (en) 2015-08-28 2020-05-12 Hanmi Pharm. Co., Ltd. Insulin analogs and use thereof
US11396534B2 (en) 2016-09-23 2022-07-26 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
CN110087674A (zh) * 2016-12-16 2019-08-02 诺和诺德股份有限公司 含胰岛素的药物组合物
CN115154591A (zh) * 2016-12-16 2022-10-11 诺和诺德股份有限公司 含胰岛素的药物组合物
CN115154591B (zh) * 2016-12-16 2023-04-14 诺和诺德股份有限公司 含胰岛素的药物组合物
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
WO2021142736A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Dosing regimen of glp-1

Also Published As

Publication number Publication date
HUS1700016I1 (hu) 2017-05-29
PL2597103T3 (pl) 2017-04-28
JP5757530B2 (ja) 2015-07-29
EP2209800B1 (en) 2013-07-24
NO2017015I2 (no) 2017-04-21
JP2012229214A (ja) 2012-11-22
BRPI0820535B1 (pt) 2020-09-29
PT2597103T (pt) 2017-02-08
DK2597103T3 (en) 2017-02-13
CN107412742A (zh) 2017-12-01
CN107412742B (zh) 2022-03-15
US8937042B2 (en) 2015-01-20
CA2705821A1 (en) 2009-05-22
HUE030383T2 (en) 2017-05-29
ES2430042T3 (es) 2013-11-18
WO2009063072A3 (en) 2010-01-07
WO2009063072A2 (en) 2009-05-22
ES2612736T3 (es) 2017-05-18
NO2017015I1 (no) 2017-04-21
MX2010005245A (es) 2010-06-01
EP2597103A1 (en) 2013-05-29
JP5241849B2 (ja) 2013-07-17
EP2597103B1 (en) 2016-11-02
EP2209800A2 (en) 2010-07-28
ZA201003019B (en) 2011-06-29
BRPI0820535B8 (pt) 2021-05-25
US20110152185A1 (en) 2011-06-23
CN107115523A (zh) 2017-09-01
BRPI0820535A8 (pt) 2016-10-18
PL2209800T3 (pl) 2013-12-31
BRPI0820535A2 (pt) 2016-06-21
JP2011503152A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
CN107412742B (zh) 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
AU2003208945B2 (en) Method for administering GLP-1 molecules
US8993516B2 (en) Meal-time insulin analogues of enhanced stability
KR101852328B1 (ko) 메티오닌을 함유하는 수성 인슐린 제제
US8192957B2 (en) Fibrillation-resistant insulin and insulin analogues
JP5832439B2 (ja) Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
JP5675799B2 (ja) 遅効性インスリン製剤
JP2005508895A (ja) Ｇｌｐ−１および基礎インスリンの予備混合物
CN101854948A (zh) 含有胰岛淀粉样多肽类和长效胰岛素的合剂
US20150299286A1 (en) Glutamic acid-stabilized insulin analogues
CN104010652A (zh) 超浓缩的速效胰岛素类似物制剂
US12312390B2 (en) Rapid-acting insulin analogues of enhanced stability
WO2025232124A1 (en) Pharmaceutical compositions and their uses, and methods for improving the storage stability of pharmaceutical compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20101013

WW01 Invention patent application withdrawn after publication